More than three-quarters of lupus patients taking obinutuzumab (Gazvya) had a significant improvement in their symptoms after a year on the drug, researchers reported March 6 in The New England ...
Phase 3 trial data show that obinutuzumab significantly reduces disease activity in very active extrarenal lupus.
Patients with lupus nephritis complicated by thrombotic microangiopathy tend to have high death risk and poor renal outcomes. They need vital and effective therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results